APGE VS PLRX Stock Comparison

Performance

APGE
28/100

APGE returned -16.93% in the last 12 months. Based on SPY's performance of -13.93%, its performance is below average giving it a score of 28 of 100.

PLRX
10/100

PLRX returned -39.67% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Earnings

APGE
100/100

APGE has missed earnings 1 times in the last 20 quarters.

PLRX
10/100

PLRX has missed earnings 5 times in the last 20 quarters.

Volatility

APGE
44/100

APGE has had a lower than average amount of volatility over the last 12 months giving it a score of 44 of 100.

PLRX
39/100

PLRX has had a lower than average amount of volatility over the last 12 months giving it a score of 39 of 100.

Sentiment

APGE

"Sentiment" not found for APGE

PLRX
80/100

PLRX had a bullish sentiment score of 80.05% across Twitter and StockTwits over the last 12 months. It had an average of 1.82 posts, 0.00 comments, and 0.09 likes per day.

Technicals

APGE

"Technicals" not found for APGE

PLRX
11/100

PLRX receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.

Profit

APGE

"Profit" not found for APGE

PLRX
10/100

Out of the last 19 quarters, PLRX has had 2 profitable quarters and has increased their profits year over year on 0 of them.

All score calculations are broken down here to help you make more informed investing decisions

Apogee Therapeutics, Inc. Common Stock Summary

Nasdaq / APGE

Healthcare

Biotechnology

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.

Pliant Therapeutics, Inc. Common Stock Summary

Nasdaq / PLRX

Healthcare

Biotechnology

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition, it is developing two additional preclinical integrin-based programs, which include an oncology program, as well as a program for an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor for treatment of muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Power up your portfolio